Reactivity of CK7 across the spectrum of renal cell carcinomas with clear cells.


Journal

Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 20 08 2018
revised: 12 11 2018
accepted: 13 11 2018
pubmed: 18 11 2018
medline: 14 6 2019
entrez: 17 11 2018
Statut: ppublish

Résumé

Current available data on cytokeratin 7 (CK7) immunostaining pattern in the clear cell renal cell carcinoma (RCC) spectrum is conflicting. The aim of this study was to assess CK7 immunoreactivity within the spectrum of clear cell renal neoplasms, including clear cell RCC, multicystic renal neoplasm of low malignant potential and clear cell papillary RCC-like tumours. We analysed two clones of CK7 and two tumour blocks for a total of 75 cases divided into five distinct groups: (i) low-grade clear cell RCC, (ii) high-grade clear cell RCC, (iii) multicystic renal neoplasm of low malignant potential, (iv) clear cell RCC with cystic changes and (v) clear cell papillary RCC-like tumours. We found the highest CK7 reactivity in low-grade clear cell RCC, multicystic renal neoplasm of low malignant potential and clear cell papillary RCC-like groups, ranging from 60% to 93%. Our findings show that CK7 immunoreactivity in clear cell RCC is variable, and the extent of staining depends on the grade and architectural growth patterns of the tumours.

Identifiants

pubmed: 30444288
doi: 10.1111/his.13791
doi:

Substances chimiques

Biomarkers, Tumor 0
Keratin-7 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

608-617

Subventions

Organisme : Charles University Research Fund
ID : Q39
Organisme : Charles University Research Fund
ID : FN 00669806

Informations de copyright

© 2018 John Wiley & Sons Ltd.

Auteurs

Manuel L Gonzalez (ML)

Department of Pathology, University of Kansas, Medical Center, Kansas City, Kansas, USA.

Reza Alaghehbandan (R)

Department of Pathology, Faculty of Medicine, University of British Columbia, Royal Columbian Hospital, Vancouver, BC, Canada.

Krystina Pivovarcikova (K)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Kvetoslava Michalova (K)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Joanna Rogala (J)

Department of Pathology, University Hospital Wroclaw, Wroclaw, Poland.

Petr Martinek (P)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

María P Foix (MP)

Department of Pathology, Bellvitge Biomedical Research Institut (IDIBELL), Bellvitge University Hospital, University of Barcelona School of Medicine, L'Hospitalet de Llobregat, Barcelona, Spain.

Enric C Mundo (EC)

Department of Pathology, Bellvitge Biomedical Research Institut (IDIBELL), Bellvitge University Hospital, University of Barcelona School of Medicine, L'Hospitalet de Llobregat, Barcelona, Spain.

Eva Comperat (E)

Department of Pathology, Hospital Tenon, Paris, Sorbonne University, Paris, France.

Monika Ulamec (M)

'Ljudevit Jurak' Pathology Department, Clinical Hospital Center 'Sestre milosrdnice', Pathology Department, Medical University, Medical Faculty Zagreb, Zagreb, Croatia.

Milan Hora (M)

Department of Urology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Michal Michal (M)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Ondrej Hes (O)

Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH